Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The United States Food and Drug Administration issued a Black Box warning in October 2004 after placebo-controlled trials of antidepressant medications found an increased risk of suicidal thoughts and behaviors among children and adolescents taking antidepressant medications relative to placebo. Subsequently, some researchers have concluded that the Black Box warning caused severe unintended consequences; specifically, they have argued that the warning led to reduced use of antidepressants among youth, which led to more suicides. In this paper, we critically examine research regarding the Black Box warning's alleged deleterious consequences. One study claimed that controlled trials did not actually find an increased risk of suicidality among youth taking fluoxetine relative to those taking placebo, but its measure of suicidality is likely invalid. We found that ecological time series studies claiming that decreasing antidepressant prescriptions are linked to higher rates of suicide attempts or actual suicides among youth were methodologically weak. These studies exhibited shortcomings including: selective use of time points, use of only a short-term time series, lack of performing statistical analysis, not examining level of severity/impairment among participants, inability to control confounding variables, and/or use of questionable measures of suicide attempts. Further, while some time-series studies claim that increased antidepressant prescriptions are related to fewer youth suicides, more recent data suggests that increasing antidepressant prescriptions are related to more youth suicide attempts and more completed suicides among American children and adolescents. We also note that case-control studies show increased risk of suicide attempts and suicide among youth taking antidepressants, even after controlling for some relevant confounds. As clinical trials have the greatest ability to control relevant confounds, it is important to remember such trials demonstrated increased risk of suicidality adverse events among youth taking antidepressants. The Black Box warning is firmly rooted in solid data whereas attempts to claim the warning has caused harm are based on quite weak evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 2×
“This measure seems to be more thoroughly validated in detecting contemporary suicidal events and predicting future suicidal events than suicidality items on depression rating scales described earlier (42, 43).”
BackgroundNational trends in the prevalence and treatment of depression in adolescents and young adults.
Mojtabai, R., Olfson, M., & Han, B. (2016) · Pediatrics · doi:10.1542/peds.2016-1878 · Cited by 1,424 · cited 1×
“examined the prevalence of depression among adolescents and what treatments were received during this period (80).”
BackgroundBridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Silverman, M. M., Berman, A. L., Sanddal, N. D., O'Carroll, P. W., & Joiner, T. E. (2007) · Suicide and Life-Threatening Behavior · doi:10.1521/suli.2007.37.3.264 · Cited by 991
KELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641 · cited 2×
“found double the number of suicidality events on paroxetine compared to those reported in the original journal article reporting trial results (2).”
BackgroundResultHospitalization for Suicide Ideation or Attempt: 2008–2015
Plemmons, G., Hall, M., Doupnik, S., Gay, J., Brown, C., Browning, W., Casey, R., Freundlich, K., Johnson, D. P., Lind, C., et al. (2018) · Pediatrics · doi:10.1542/peds.2017-2426 · Cited by 405
Gibbons, R. D., Hur, K., Brown, C. H., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2044 · Cited by 271 · cited 1×
“Clinical Trials Re-Analysis of Clinical Trial Data Based upon re-analyzing data from selected RCTs, Gibbons and colleagues concluded that antidepressants both possessed substantially more efficacy than had been seen in prior analyses (32) and posed no risk of increasing suicidality in youth (17).”
MethodEmslie, G. J., Ventura, D., Korotzer, A., & Tourkodimitris, S. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181a2b304 · Cited by 210
Social determinants of health and the future well-being of Aboriginal children in Canada
(2012) · Paediatrics and Child Health · doi:10.1093/pch/17.7.381 · Cited by 178
Walkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112
Offidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94 · cited 2×
“Managing Antidepressant-Induced Suicidality The term “activation” refers to a group of adverse events which include mania, irritability, insomnia, agitation, restlessness, or excessive excitability (87, 88).”
BackgroundFindling, R. L., Robb, A., & Bose, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0023 · Cited by 57 · cited 19×
“Data reporting in a RCT of citalopram in depressed youth is relevant to our above observation that the SIQ-Jr was not statistically analyzed in Findling et al.’s escitalopram trial, which was sponsored by Forest (26).”
BackgroundMethodInfluentialIgnaszewski, M. J., & Waslick, B. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0174 · Cited by 37 · cited 1×
“A recent paper by Ignaszewski and Waslick claims that three newer acute-phase trials using the C-SSRS show no sign of antidepressant-induced suicidality and “may suggest that treatment-emergent suicidality is not as significant a risk as indicated” by the FDA [(25) pg.”
BackgroundTint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13
Cited by
Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Brain Sciences · doi:10.3390/brainsci13111503 · Cited by 104
“A vast range of medications [30], including antidepressants [31–34], have been associated with both depression and suicidal ideation.”
BackgroundGraff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., et al. (2023) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwad012 · Cited by 30
“Common therapeutic options include fluoxetine, sertraline, citalopram, and fluvoxamine (99–102), with continued recommendations that suicidality should be monitored when these medications are used (103).”
BackgroundGut-focused hypnotherapy for children and adolescents with irritable bowel syndrome
Vasant, D. H., Hasan, S. S., Cruickshanks, P., & Whorwell, P. J. (2021) · Frontline Gastroenterology · doi:10.1136/flgastro-2020-101679 · Cited by 28
Metadata
- Authors
- Spielmans, G. I., Spence-Sing, T., & Parry, P.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2020-02-13
- Volume
- 11
- Pages
- 18-18
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W3005631351
- Cited by
- 60
- References
- 14
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.